GlassScriptPhysician profile
Paula J Rother
NPI 1780184754
$9,075.59
in general payments reported to CMS, 2019-2025
25 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,299 · 2022: $1,337 · 2023: $1,752 · 2024: $1,947 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,440.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,852.09 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,305.54 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,144.49 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $872.38 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $744.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $586.83 | 2021-2025 | Trintellix |
| Alkermes, INC. | $472.43 | 2021-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $354.03 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $268.68 | 2022-2025 | Auvelity |
| Corium, LLC | $248.39 | 2021-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $239.83 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $201.69 | 2021 | |
| Neurocrine Biosciences, INC. | $198.52 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $174.22 | 2023-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $125.13 | 2021-2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $97.03 | 2024-2025 | Fanapt |
| Almatica Pharma LLC | $43.73 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $30.37 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $23.27 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.35 | 2025 | |
| Neos Therapeutics, LP | $22.11 | 2024 | Adzenys Xr-Odt |
| Eisai INC. | $16.06 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.98 | 2022 | |
| Adlon Therapeutics L.P. | $11.83 | 2021 | |
| Sumitomo Pharma America, INC. | $5.37 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Rother listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.